Morgan Stanley analyst Sarita Kapila raised the firm’s price target on Roche (RHHBY) to CHF 295 from CHF 290 and keeps an Underweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche Earnings Call: Strong Growth, Deep Pipeline Momentum
- Roche reports FY25 group sales CHF 61.52B vs. CHF 60.5B last year
- Roche board proposes dividend increase to CHF 9.80 per share
- Roche expects increase in group sales in mid single digit range for FY26
- Genentech announces topline results from CT388-103 trial